A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of ozanimod compared with placebo in participants with ulcerative colitis (UC) in mainland China and Taiwan. The main study is composed of an induction period, maintenance period, safety follow-up, and participants meeting certain criteria will be given the opportunity to participate in an optional open label extension.

Official Title
-----------------
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod to Evaluate Efficacy and Long-term Safety in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Conditions
-----------------
Ulcerative Colitis

Intervention / Treatment
-----------------
* Drug: Ozanimod
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Main Study: Eligible participants must be Chinese. Participant has had moderately to severely active UC diagnosed at least 3 months prior to first investigational product administration. Open-label Extension Period: Participants who have completed the Week 10 Visit and are non-responders at Week 10. Participants who have completed the Induction Period and entered the Maintenance Period experienced disease relapse during the Maintenance Period, or who have completed the Maintenance Period at Week 52. Exclusion Criteria: Main Study and Open-label Extension Period: Participant has severe extensive colitis, diagnosis of CD, indeterminate colitis, presence or history of a fistula consistent with CD, microscopic colitis, radiation colitis, or ischemic colitis. Open-label Extension Period: Participant has clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric, or other major systemic disease making implementation of the protocol or interpretation of the study difficult or that would put the participant at risk by continuing the study or that would have required a participant to discontinue treatment were observed during the Induction Period or Maintenance Period. Participant has clinically relevant cardiovascular conditions, including history or presence of recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, Class III/IV heart failure, sick sinus syndrome, or severe untreated sleep apnea were observed during the Induction Period or Maintenance Period.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A: Ozanimod<br> | Drug: Ozanimod<br>* Specified dose on specified days<br>* Other names: BMS-986374;|
| Placebo Comparator: Arm B: Placebo<br> | Drug: Placebo<br>* Specified dose on specified days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants with clinical remission as measured by the 3-component Mayo Score |  | At week 10 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants with clinical remission as measured by the 3-component Mayo Score |  | At week 52 | 
| Proportion of participants with clinical response as measured by the 3-component Mayo Score |  | At week 10 and at week 52 | 
| Proportion of participants with endoscopic improvement |  | At week 10 and at week 52 | 
| Proportion of participants achieving histologic remission |  | At week 10 and at week 52 | 
| Proportion of participants with mucosal healing |  | At week 10 and at week 52 | 
| Proportion of participants in remission as measured by the 3-component Mayo Score while off corticosteroids for ≥ 12 weeks |  | At week 52 | 
| Proportion of participants with Treatment Emergent Adverse Events (TEAEs) |  | Up to 78 weeks | 
| Proportion of participants with Serious Adverse Events (SAEs) |  | Up to 78 weeks | 
| Proportion of participants with TEAEs leading to discontinuation of investigational product |  | Up to 78 weeks | 
| Proportion of participants with TEAEs of special interest |  | Up to 78 weeks | 
| Proportion of participants with clinical laboratory abnormalities |  | Up to 78 weeks | 
| Proportion of participants with vital sign abnormalities |  | Up to 78 weeks | 
| Proportion of participants with electrocardiogram (ECG) abnormalities |  | Up to 78 weeks | 
| Proportion of participants with pulmonary function test abnormalities |  | Up to 78 weeks |